Indication for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. also indicated for the treatment of adults with philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.pharmacodynamics dasatinib is an oral dual bcr/abl and src family tyrosine kinase inhibitorsmechanism of action dasatinib, at nanomolar concentrations, inhibits the following kinases: bcr-abl, src family (src, lck, yes, fyn), c-kit, epha2, and pdgfr?. based on modeling studies, dasatinib is predicted to bind to multiple conformations of the abl kinase. in vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. dasatinib inhibited the growth of chronic myeloid leukemia (cml) and acute lymphoblastic leukemia (all) cell lines overexpressing bcr-abl. under the conditions of the assays, dasa